KPC Pharmaceuticals

KPC Pharmaceuticals FCF Margin

The Free Cash Flow Margin of KPC Pharmaceuticals (600422.SS) as of Nov 4, 2026 is 3.02 %. In the previous year, Free Cash Flow Margin was 8.67 % — a change of -65.17% (lower).

FCF Margin

3.02 %

YoY

-65.17%

Last updated:

Free Cash Flow Margin of KPC Pharmaceuticals is 2025 3.02 % . Free Cash Flow Margin of KPC Pharmaceuticals was 2024 8.67 % . It decreases by -65.17% lower compared to the previous year.

The KPC Pharmaceuticals FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
1.90 CNY
Jan 1, 2019
1.01 CNY
Jan 1, 2020
3.26 CNY
Jan 1, 2021
0.19 CNY
Jan 1, 2022
1.84 CNY
Jan 1, 2023
7.65 CNY
Jan 1, 2024
8.67 CNY
Jan 1, 2025
3.02 CNY
The KPC Pharmaceuticals FCF Margin history
YEARFCF MarginYoY
3.02 %-65.17%
8.67 %+13.41%
7.65 %+316.28%
1.84 %+881.05%
0.19 %-94.25%
3.26 %+221.74%
1.01 %-46.70%
1.90 %-523.97%
-0.45 %-121.20%
2.11 %-60.95%
5.41 %+49.45%
3.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KPC Pharmaceuticals Stock analysis

What does KPC Pharmaceuticals do? KPC Pharmaceuticals, Inc. generates revenue through the research, development, manufacturing, and international marketing of its diverse drug portfolio. The company sells natural herbal medicines, traditional Chinese medicines, and chemical synthetic drugs, including central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines, and anti-inflammatory drugs. Its main customers are healthcare providers, hospitals, and pharmaceutical distributors globally. The firm also produces health products and offers medical services as additional revenue streams. The company's product segments are defined by therapeutic categories such as central nervous system treatments, cardiovascular care, and anti-inflammatory solutions. These products target both domestic and international markets, with a focus on traditional Chinese medicine and natural herbal formulations. Sales are driven by wholesale distribution networks and direct commercial partnerships in the pharmaceutical industry. KPC Pharmaceuticals' revenue model combines product sales from its core drug lines with supplementary health product offerings and medical service provision. The business leverages its manufacturing capabilities in Kunming, Yunnan to serve global markets, with a strong emphasis on traditional Chinese medicine and natural herbal medicine segments. The firm's international marketing efforts support its presence in multiple regions. KPC Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KPC Pharmaceuticals stock

Free Cash Flow Margin of KPC Pharmaceuticals is 3.02 % in 2025.

Free Cash Flow Margin of KPC Pharmaceuticals changed from 8.67 % to 3.02 %, representing a -65.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin KPC Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's KPC Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — KPC Pharmaceuticals

All Key Metrics — KPC Pharmaceuticals